Elixinol Wellness Limited
Elixinol Wellness Limited (ELLXF) Financial Performance & Income Statement Overview
Explore the financials of Elixinol Wellness Limited (ELLXF), including yearly and quarterly data on income, cash flow, and balance sheets.
Elixinol Wellness Limited (ELLXF) Income Statement & Financial Overview
View the income breakdown for Elixinol Wellness Limited ELLXF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $8.18M | $6.77M | $4.81M | $2.41M |
| Cost of Revenue | $5.24M | $4.36M | $5.49M | $1.55M |
| Gross Profit | $2.94M | $2.42M | -$671000.00 | $857000.00 |
| Gross Profit Ratio | $0.36 | $0.36 | -$0.14 | $0.36 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $4.44M | $4.38M | $2.23M | $2.22M |
| Operating Expenses | $4.44M | $4.38M | $2.23M | $2.91M |
| Total Costs & Expenses | $9.69M | $8.74M | $7.71M | $4.46M |
| Interest Income | $0.00 | $23000.00 | $73000.00 | $0.00 |
| Interest Expense | $0.00 | $66000.00 | $73000.00 | $0.00 |
| Depreciation & Amortization | $274000.00 | $266000.00 | $333000.00 | $41500.00 |
| EBITDA | -$2.14M | -$2.37M | -$1.37M | -$1.37M |
| EBITDA Ratio | -$0.26 | -$0.35 | -$0.53 | -$0.57 |
| Operating Income | -$1.50M | -$1.97M | -$2.90M | -$1.41M |
| Operating Income Ratio | -$0.18 | -$0.29 | -$0.60 | -$0.59 |
| Other Income/Expenses (Net) | -$1.05M | -$790000.00 | -$696500.00 | -$642500.00 |
| Income Before Tax | -$2.56M | -$2.75M | -$4.11M | -$2.06M |
| Income Before Tax Ratio | -$0.31 | -$0.41 | -$0.85 | -$0.85 |
| Income Tax Expense | -$3.59M | $1000.00 | $1000.00 | $500.00 |
| Net Income | $1.03M | -$2.76M | -$4.11M | -$2.06M |
| Net Income Ratio | $0.13 | -$0.41 | -$0.85 | -$0.85 |
| EPS | $0.006 | -$0.003 | -$0.005 | -$0.004 |
| Diluted EPS | $0.006 | -$0.003 | -$0.005 | -$0.004 |
| Weighted Avg Shares Outstanding | $184.38M | $984.64M | $813.52M | $582.29M |
| Weighted Avg Shares Outstanding (Diluted) | $184.36M | $997.92M | $813.52M | $586.82M |
The company's financials show resilient growth, with revenue advancing from $2.41M in Q3 2023 to $8.18M in Q4 2024. Gross profit remained healthy with margins at 36% in Q4 2024 compared to 36% in Q3 2023. Operating income hit -$1.50M last quarter, sustaining a consistent -18% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.14M. Net income rose to $1.03M, while earnings per share reached $0.006. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan